Goldman Sachs
HCAT icon

Goldman Sachs’s Health Catalyst HCAT Stock Holding History

Goldman Sachs’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Buy
480,970
+93,798
+24% +$135K ﹤0.01% 5248
2026
Q1 		$492K Buy
387,172
+70,370
+22% +$132K ﹤0.01% 5609
2025
Q4 		$757K Sell
316,802
-242,850
-43% -$664K ﹤0.01% 5328
2025
Q3 		$1.6M Buy
559,652
+145,740
+35% +$499K ﹤0.01% 4675
2025
Q2 		$1.56M Sell
413,912
-142,013
-26% -$559K ﹤0.01% 4367
2025
Q1 		$2.52M Sell
555,925
-330,742
-37% -$1.75M ﹤0.01% 3958
2024
Q4 		$6.27M Buy
886,667
+263,749
+42% +$2.1M ﹤0.01% 3221
2024
Q3 		$5.07M Sell
622,918
-265,256
-30% -$1.92M ﹤0.01% 3329
2024
Q2 		$5.68M Sell
888,174
-388,641
-30% -$2.49M ﹤0.01% 3036
2024
Q1 		$9.61M Buy
1,276,815
+56,188
+5% +$513K ﹤0.01% 2486
2023
Q4 		$11.3M Buy
1,220,627
+335,823
+38% +$2.74M ﹤0.01% 2406
2023
Q3 		$8.95M Sell
884,804
-368,164
-29% -$4.4M ﹤0.01% 2484
2023
Q2 		$15.7M Sell
1,252,968
-304,383
-20% -$3.63M ﹤0.01% 2053
2023
Q1 		$18.2M Buy
1,557,351
+119,395
+8% +$1.52M ﹤0.01% 1891
2022
Q4 		$15.3M Sell
1,437,956
-437,328
-23% -$4.22M ﹤0.01% 2194
2022
Q3 		$18.2M Buy
1,875,284
+447,890
+31% +$5.93M ﹤0.01% 1954
2022
Q2 		$20.7M Buy
1,427,394
+1,160,763
+435% +$19.8M 0.01% 1862
2022
Q1 		$6.97M Buy
266,631
+139,427
+110% +$3.96M ﹤0.01% 3033
2021
Q4 		$5.04M Sell
127,204
-55,590
-30% -$2.53M ﹤0.01% 3400
2021
Q3 		$9.14M Buy
182,794
+81,754
+81% +$4.46M ﹤0.01% 2821
2021
Q2 		$5.61M Buy
101,040
+70,712
+233% +$3.77M ﹤0.01% 3232
2021
Q1 		$1.42M Sell
30,328
-53,928
-64% -$2.61M ﹤0.01% 4323
2020
Q4 		$3.67M Sell
84,256
-128,761
-60% -$4.75M ﹤0.01% 3249
2020
Q3 		$7.8M Buy
213,017
+184,735
+653% +$6.27M ﹤0.01% 2532
2020
Q2 		$825K Buy
28,282
+696
+3% +$19.2K ﹤0.01% 4084
2020
Q1 		$721K Buy
+27,586
New +$843K ﹤0.01% 3973
2019
Q4 		– Sell
-7,883
Closed -$249K – 5299
2019
Q3 		$249K Buy
+7,883
New +$310K ﹤0.01% 4749

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $239M AUM
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's HCAT Position: Q2 2026 in Review

Goldman Sachs increased its Health Catalyst (HCAT) stake by 24% in Q2 2026, buying an estimated $135K and bringing the position to 480,970 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #5248.

Goldman Sachs first reported a position in HCAT in Q3 2019 and has held it in 27 quarters since. The position peaked at $20.7M in Q2 2022. 127 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Goldman Sachs held 480,970 shares of Health Catalyst worth $957K as of Q2 2026.
  • Goldman Sachs bought 93,798 Health Catalyst shares in Q2 2026, an estimated $135K.
  • Health Catalyst made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5248 holding.
  • Goldman Sachs first reported a position in Health Catalyst in Q3 2019 and has held it in 27 quarters since.
  • Goldman Sachs's Health Catalyst position peaked at $20.7M in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.